294 related articles for article (PubMed ID: 38415245)
1. T cell senescence: a new perspective on immunotherapy in lung cancer.
Huang M; Wang Y; Fang L; Liu C; Feng F; Liu L; Sun C
Front Immunol; 2024; 15():1338680. PubMed ID: 38415245
[TBL] [Abstract][Full Text] [Related]
2. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
5. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
Zhao Y; Shao Q; Peng G
Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
[TBL] [Abstract][Full Text] [Related]
6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
7. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
8. Immunosenescence: a key player in cancer development.
Lian J; Yue Y; Yu W; Zhang Y
J Hematol Oncol; 2020 Nov; 13(1):151. PubMed ID: 33168037
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
10. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy.
Liu X; Hoft DF; Peng G
J Clin Invest; 2020 Mar; 130(3):1073-1083. PubMed ID: 32118585
[TBL] [Abstract][Full Text] [Related]
11. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment.
Deng Y; Chen Q; Yang X; Sun Y; Zhang B; Wei W; Deng S; Meng J; Hu Y; Wang Y; Zhang Z; Wen L; Huang F; Wan C; Yang K
Theranostics; 2024; 14(3):1224-1240. PubMed ID: 38323313
[No Abstract] [Full Text] [Related]
14. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
15. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
Gong Z; Jia Q; Chen J; Diao X; Gao J; Wang X; Zhu B
J Thorac Oncol; 2019 May; 14(5):857-866. PubMed ID: 30768970
[TBL] [Abstract][Full Text] [Related]
16. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
17. The Evolving Role of CD8
Huff WX; Kwon JH; Henriquez M; Fetcko K; Dey M
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181772
[TBL] [Abstract][Full Text] [Related]
18. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
19. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
20. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
